BIT:PHN - Euronext Milan - IT0005274094 - Common Stock - Currency: EUR
BIT:PHN (5/23/2025, 7:00:00 PM)
49.6
-0.6 (-1.2%)
The current stock price of PHN.MI is 49.6 EUR. In the past month the price decreased by -3.31%. In the past year, price decreased by -1.2%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LOR.DE | L'OREAL | 29.5 | 199.54B | ||
OR.PA | L'OREAL | 29.46 | 199.27B | ||
UNVB.DE | UNILEVER PLC | 24.45 | 137.40B | ||
UNA.AS | UNILEVER PLC | 24.44 | 137.30B | ||
BEI.DE | BEIERSDORF AG | 29.74 | 29.87B | ||
COTY.PA | COTY INC-CL A | 19.92 | 3.65B | ||
ITP.PA | INTERPARFUMS SA | 19.38 | 2.76B | ||
ICOS.MI | INTERCOS SPA | 29.66 | 1.34B | ||
ONTEX.BR | ONTEX GROUP NV | 12.86 | 625.04M | ||
JBOG.PA | JACQUES BOGART | 19.23 | 78.45M | ||
ENV.MI | ENERVIT | 14 | 57.32M |
Pharmanutra SpA develops nutraceutical products and medical devices. The company is headquartered in Pisa, Pisa and currently employs 115 full-time employees. The company went IPO on 2017-07-18. The firm develops nutraceutical products and medical devices. The company focuses on studying and producing formulations that are backed up in scientific research. The company is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The firm offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.
PHARMANUTRA SPA
Via delle Lenze n. 216/B
Pisa PISA IT
Employees: 115
Phone: 390507846500
The current stock price of PHN.MI is 49.6 EUR. The price decreased by -1.2% in the last trading session.
The exchange symbol of PHARMANUTRA SPA is PHN and it is listed on the Euronext Milan exchange.
PHN.MI stock is listed on the Euronext Milan exchange.
7 analysts have analysed PHN.MI and the average price target is 84.66 EUR. This implies a price increase of 70.69% is expected in the next year compared to the current price of 49.6. Check the PHARMANUTRA SPA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
PHARMANUTRA SPA (PHN.MI) has a market capitalization of 480.13M EUR. This makes PHN.MI a Small Cap stock.
PHARMANUTRA SPA (PHN.MI) currently has 115 employees.
PHARMANUTRA SPA (PHN.MI) has a support level at 48.62 and a resistance level at 51.03. Check the full technical report for a detailed analysis of PHN.MI support and resistance levels.
The Revenue of PHARMANUTRA SPA (PHN.MI) is expected to grow by 14.39% in the next year. Check the estimates tab for more information on the PHN.MI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PHARMANUTRA SPA (PHN.MI) has a dividend yield of 1.93%. The yearly dividend amount is currently 0.85. Check the full fundamental report for a detailed analysis of PHN.MI dividend history, reliability and sustainability.
The PE ratio for PHARMANUTRA SPA (PHN.MI) is 20.24. This is based on the reported non-GAAP earnings per share of 2.45 and the current share price of 49.6 EUR. Check the full fundamental report for a full analysis of the valuation metrics for PHN.MI.
ChartMill assigns a fundamental rating of 7 / 10 to PHN.MI. Both the health and profitability get an excellent rating, making PHN.MI a very profitable company, without any liquidiy or solvency issues.
Over the last trailing twelve months PHN.MI reported a non-GAAP Earnings per Share(EPS) of 2.45. The EPS increased by 13.49% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 14.11% | ||
ROA | 20.02% | ||
ROE | 37.82% | ||
Debt/Equity | 0.32 |
ChartMill assigns a Buy % Consensus number of 83% to PHN.MI. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 16.46% and a revenue growth 14.39% for PHN.MI